X-82
As of the edition of 20 October 2026, X-82 is a drug: stopped in 2020; acts on FLT1, FLT4 and KDR and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Unknown
- Registered trials
- 5, 2 stopped early
- Disease areas
- Cancer; Eye; Digestive system; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product5 company-target rows are on route A because of X-82.
See the 5 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 3 | 1 | 0 | 2 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Tyrogenex | Lead sponsor of trials | 2011 to now |